Effect of dietary energy and previous bovine somatotropin on milk yield, mastitis, and reproduction in dairy cows.

Thirty multiparous lactating Holstein cows were blocked according to time of calving and assigned to a 2 x 3 factorial arrangement of treatments in a randomized complete block design to evaluate the effects of two dietary energy concentrations either without or with bST (20.6 mg/d per cow) administered to cows that had not or had received bST during the preceding lactation. Subcutaneous injection of bST began 28 to 35 d postpartum and continued for 39 wk. The dietary energy concentration x bST interaction was not significant for any response variable. Compared with DMI of control cows, DMI was higher for cows receiving bST, being 1.6 and 2.4 kg/d higher for cows receiving bST for one and two lactations, respectively. Milk, fat, and protein yields were higher for cows receiving bST than for controls. Those receiving bST for a second lactation also produced more milk than controls until wk 20; thereafter, milk yields were similar to those of controls. Somatotropin administration had no adverse effect on udder health. Cows receiving bST tended to ovulate less regularly than controls, which may be attributed to their higher milk yield. However, BW gains during lactation were similar for all treatments, indicating that bST-treated cows built energy reserves for the subsequent lactation. Although energy concentrations of the diets had no significant impact on yield, the higher energy diet tended to depress milk fat concentration. Administration of bST to dairy cows for a second, consecutive lactation yielded responses similar for the first 20 wk of the study to those receiving bST for the first time. However, after wk 20, milk yield was less than that by cows receiving bST for the first lactation but similar to that of control cows.     

Overall efficacy of chronically administered recombinant bovine somatotropin to lactating dairy cows

Recombinant bST at daily dosages of 0, 10.3, 20.6, and 41.2 mg/d were injected for 266 d into 8, 10, 9, and 9 Holstein cows, respectively. Treatment effects of recombinant bST were assessed for milk production traits, BW, blood components, and health and reproductive variables. Data reported compare controls to all bST-treated cows. There was an average increase of 18% in 3.5% FCM for bST versus control cows. This increase resulted in enhanced feed efficiency for bST cows, as their DM intakes were not elevated above those of the control cows. Recovery of BW was similar between control and bST groups. Milk composition was unaffected except for a slight decrease in protein percentage during the first 9 wk of treatment, and an elevated SCC between wk 19 and 28. Blood parameters were not different between control and bST cows, except for hematocrit, which decreased with bST treatment. The only health and reproductive parameters affected by bST were mastitis and days open, which were increased in the highest dosage groups.     

Recombinant bovine somatotropin with lactating cows fed diets differing in energy density

Sixty-four Holstein cows (32 primiparous) were assigned randomly at parturition to one of two diets differing in forage:grain ratio and were further assigned to either control or treatment with recombinant bST. A full lactation study was conducted. Total mixed rations consisted of alfalfa silage, high moisture ear corn, soybean meal, and vitamin and mineral supplements. Percentages of forage in the diet (dry basis) for the high and medium energy diets were wk 1 to 12, 38.2 and 58.2; wk 13 to 26, 48.2 and 68.2; and wk 27 to 44, 68.2 and 88.2. Injection of a saline placebo or 20.6 mg/d per cow of bST started at wk 13 and stopped at wk 43 of lactation. Administration of bST increased 305-d milk yield by 19.9 and 18.3% for multiparous cows fed high and medium grain diets and by 13.0 and 5.9% for primiparous cows fed the same diets. Body weight gain during lactation tended to be lower for cows treated with bST, and body condition scores were significantly lower for those treated with bST and fed the medium energy diets. Daily injection of bST did not change concentrations of glucose or urea in blood or beta-hydroxybutyrate in plasma. Multiparous cows had a transitory increase in plasma FFA concentration immediately after bST treatment started. Milk composition, health, and reproductive parameters observed were not adversely affected by bST administration. Cows fed low energy diets during bST administration in the first lactation did not produce as much milk as controls when compared during the first 10 wk of their second lactation.     

Effect on production traits of bovine somatotropin for up to three consecutive lactations.

Thirteen (control) cows were injected daily with saline and 22 with bST (12 at 10.3 mg/d and 10 at 20.6 mg/d) through wk 5 to 42 of lactation. Nine of the treated cows had received bST in the previous lactation, and 7 cows received bST in the previous two lactations. All control cows and 6 treated cows had not previously received bST. Treatment with bST caused substantial increases in milk production, feed intake, and efficiency of feed conversion in the current lactation, which is consistent with previous trials. Increases in feed intake were established fully within 9 wk of starting bST administration, somewhat earlier than usually reported. Treatment with bST in one or two previous lactations caused a statistically significant 14% reduction in production and 8% reduction in efficiency of feed conversion during the first 9 wk of bST treatment in the current lactation; reductions observed later in lactation were not statistically significant. Differences for other traits were not statistically significant. In combination with earlier trials, these results suggest that, although bST has beneficial effects on production and efficiency traits, these benefits may be considerably lower in the second and subsequent lactations of bST use. However, carry-over effects on cows not receiving bST in the current lactation were not explored in this trial.     

Response to recombinant bovine somatotropin in dairy cows with different genetic merit for milk production

Thirty-nine multiparous cows obtained from two genetic lines were utilized to determine the effect of genetic merit on lactation response to long-term administration of recombinant bST. Cow index ranged from -70 to 456 (mean = 183) and -494 to -88 (mean = -288) kg milk for high and low genetic groups, respectively. Cows were blocked by calving date and randomly assigned to treatment within genetic group. Treatments were 0, 10.3, 20.6, and 30.9 mg somatotropin injected daily from wk 14 through 44 postpartum. Cows were fed one of two total mixed rations. Diet 1 (NE1 = 1.65 Mcal/kg, CP = 18%, and ADF = 22%) was fed from start of lactation to at least 4 wk after initiation of treatment. Cows were switched to diet 2 (NE1 = 1.56 Mcal/kg, CP = 16%, and ADF = 27%) when milk output fell below 25 kg/d. Forty-four week lactation yields were 9800 and 9447 kg milk; 364 and 354 kg fat; and 322 and 309 kg protein for high and low genetic groups, respectively. Milk, milk fat, or protein yield due to somatotropin did not differ between genetic groups. Increasing dosage of bST increased milk, 4% FCM, fat, and protein yields in a linear fashion. Percentages of fat and protein of milk were similar for all treatment groups. Body weight changes were not significantly different among treatments, but condition score changes decreased linearly with increasing dose of bST. Long-term treatment with recombinant bST had no apparent effect on incidence of health problems or reproduction.     

Lactational evaluation of recombinant bovine somatotropin with corn and barley diets

Forty-eight Holstein cows were randomly assigned to receive diets containing corn or barley as the primary energy concentrate from wk 4 through 44 postpartum. During wk 14, cows from each grain source group were randomly assigned to receive 0 (control), 10.3, 20.6, and 30.9 mg/cow per d of recombinant bST injected wk 15 through 44 postpartum. Grain source exerted no significant effect on production parameters and efficacy of bST, although milk production tended to be higher with corn diets. Milk production (24.2, 29.2, 31.7, and 29.5 kg/d) and 4% FCM (21.9, 26.2, 28.1, and 28.0 kg/d) were higher for cows injected with bST, and DM intakes (20.9, 22.8, 22.0, and 23.3 kg/d) increased slightly. Percentages of milk fat (3.47, 3.28, 3.39, and 3.52) and protein (3.48, 3.44, 3.44, and 3.38) varied. Lactose, SCC, and body weights were similar for bST and dietary treatments. Diet or bST had no detectable affect on health or reproduction. Injection of bST wk 15 through 44 increased milk production 21 to 31% relative to control animals. Limiting bST use to the latter two-thirds of lactation resulted in an 8 to 17% increase in total yield with only a 0 to 5% increase in lactational DM intake.     

Dose response to recombinant bovine somatotropin from weeks 15 to 44 postpartum in lactating dairy cows

Forty Holstein cows were used in an experiment to determine the response of cows to daily subcutaneous injections of 0, 10.3, 20.6, and 30.9 mg of recombinant bST. Injections began between 98 and 104 d postpartum and continued for 29 wk, up to 70 d prepartum, or a maximum of 400 d postpartum. Increasing recombinant bST increased milk yield and 3.5% FCM yield in a linear fashion and by 5.2 and 5.7 kg/d, respectively. Milk composition was not changed, and DM intake as a percentage of BW increased from 3.39 to 3.80% with increasing (30.9 mg/d) bST. Feed efficiency (3.5% FCM/DM intake) was increased from 1.35 to 1.64 with increasing dose, suggesting improved efficiency of use of DM intake, primarily by dilution of maintenance. Increasing bST reduced BW gain linearly from .46 kg/d for the control to .22 kg/d for the 30.9 mg/d bST. Calf birth weight, weight of cows at calving, and incidence of metabolic diseases during subsequent calving were not affected by bST. Somatotropin treatment resulted in somewhat smaller increased in milk yield than that reported in previous studies. Long-term health effects and effects on reproduction could not be determined from the relatively few cows used in this study.     

Responses by lactating cows in commercial dairy herds to recombinant bovine somatotropin

Cows (890) in 15 US herds were assigned randomly in equal numbers to control or bST injections (500 mg in a prolonged-release form every 14 d for 12 wk) within three stages of lactation (57 to 100, 101 to 140, and 141 to 189 d postpartum) and two parity groups (primiparous and multiparous). Yield and milk composition were monitored 1 d/wk for 16 wk including 2 wk pretreatment and 2 wk posttreatment. Increases in milk and FCM due to bST injections were less at 57 to 100 d than at 101 to 189 d postpartum (milk 3.6 vs. 5.5; FCM 3.9 vs. 6.1 kg/d per cow), and increases in milk and FCM were more for multiparous than for primiparous cows (milk 5.5 vs. 4.2; FCM 6.0 vs. 4.7 kg/d cow). Temporarily, concentration of milk fat increased and protein decreased; later, concentrations for control and injected cows were similar. Postinjection milk fat concentration decreased, but milk protein concentration increased temporarily. The net increase in milk (and FCM) varied significantly among herds from 2.9 to 7.6 kg/d per cow (mean, 4.9 kg). Responses in FCM were similar over a wide range of pretreatment yields. A great variety of feed ingredients were fed as total mixed rations, and nutrient concentrations varied greatly. The SCC were similar before, during, and after treatment, but increase in FCM of injected cows exhibited a negative correlation with pretreatment SCC. Changes in body condition score of sometribove-injected cows varied among herds (.25 to -.45) and averaged -.02 compared with .07 for controls. There was no pattern in incidence of mastitis during sometribove injections.     

Serum immunoglobulin profiles of dairy cows chronically treated with recombinant bovine somatotropin

The objective of this study was to determine the effects of exogenous somatotropin on blood profiles of the major bovine Ig isotypes. Holsteins were treated with either 0, 10.3, or 20.6 mg recombinant bST/d. Subcutaneous injections were started between wk 4 and 5 of lactation and continued for 266 d. Blood samples were collected by coccygeal venipuncture throughout lactation for serum IgG, G1, G2, A, and M concentration determination. Cows treated with 10.3 mg of bST/d exhibited modest increases in mean blood concentrations of IgG (12.4%) and IgG2 (18.4%) relative to the other groups of cows. In addition, treated cows had 10.1% higher average concentration of IgA than controls. Somatotropin did not influence average lactational concentrations of IgG1 or IgM, although the group receiving 10.3 mg/d had higher late lactation concentrations of IgG1 than did the other two groups. However, treatment mean isotype concentrations were always within normal ranges, except for IgG2 from the 10.3 mg/d group, which were higher. The practical significance of elevated serum Ig concentrations observed in the present study is not known. However, the present data do show that bST administered at doses that increased milk yield had no apparent detrimental effect on humoral immunity as measured by blood concentrations of Ig.     

Slow release somatotropin in dairy heifers and cows fed two levels of energy concentrate. 1. Performance and body condition.

Fifty-two Holstein dairy cows (27 primiparous) were used in a 2 x 2 factorial design during wk 9 to 39 of lactation to assess the effects of slow release recombinant bST (500 mg injected at 14-d intervals) and the effects of the level of energy concentrate in the diet on dairy performance. After a winter period, cows were turned out to pasture at wk 24 of lactation. During winter, cows given low concentrate (2.5 vs. 5.4 kg DM/d) ate significantly more corn silage (13.9 vs. 11.9 kg DM/d), so that treatment had no significant effect on any measured parameter. The milk yield of bST-supplemented cows increased by 2.1 kg/d (11.0%) throughout the total experimental period. The response did not differ according to parity. Milk fat content and SCC were not altered, but milk protein was lower (.8 g/kg) from cows receiving bST during winter, and lactose increased (.5 g/kg). Lactation curves of bST-supplemented cows showed a cyclic response in milk production. Gross efficiency of milk yield was improved (.18 units) by bST administration without change in diet digestibility. No difference due to bST was found in the health or reproduction of cows. Live weight change did not differ among the groups. Multiparous cows gained body condition (bST-supplemented animals gained less than controls: .1 vs. .7 point on a five-point scale; NS). Control primiparous cows gained body condition (.1 point) but bST-supplemented cows significantly lost body condition (1.4 point).     

Milk yield of dairy cows receiving somatotropin (somavubove) daily with periodic 14-day interruption.

Thirty multiparous (cows) and 15 primiparous (heifers) lactating Holstein cattle were used in a 112-d study to examine the effects of pattern of administration of recombinantly derived bST on 3.5% FCM yield. Ten cows and 5 heifers each received either no injection (controls), 14 mg of bST daily, or four repetitions of 14 mg of bST/d for 14 d followed by 14 d of no injection (intermittent bST). Because there was an interaction between treatment groups and parity, analyses were performed separately for cows and heifers. All cows and heifers produced more FCM when given bST than controls. Comparing FCM only during the last 7 d of each period of injection for the intermittent bST group with contemporary daily injected cattle indicated that cows produced equivalent amounts of milk at those times, whereas heifers given daily bST produced 3.4 kg/d more than intermittently injected animals. Furthermore, over each of the four repetitive periods, cows and heifers given daily or intermittent bST responded similarly, although heifers given continuous bST produced more FCM than the intermittent group during each of periods 2 through 4. We conclude that daily administration of bST lends itself to dosing termination during established lactation with concomitant decline of FCM; resumption of bST allows milk yields of cows to achieve levels comparable with those prior to short-term interruption.     

Lactational response of Jersey cows to bovine somatotropin administered daily or in a sustained-release formulation.

Twenty-four Jersey cows were administered either 0 or 15.5 mg of bST/d or 310 mg of bST/14 d to determine the effect on milk yield, milk composition, feed intake, and body weight. Administration of bST was from wk 14 through 42 postpartum. Cows were housed in a tie-stall barn and fed for ad libitum intake a TMR adjusted to one of two energy protein densities according to milk yield. Milk yield of cows administered bST daily or by sustained-released vehicle increased 27.6 and 24.7%, respectively, over that of control cows; FCM increased by 30.3 and 26.7%. Percentages of fat and protein in milk were unaffected by bST treatment. Dry matter intake of cows administered bST was greater than that of control cows, whether expressed as kilograms per day or as a percentage of body weight. Apparent efficiency of yield increased in cows administered bST. No significant change in body weight occurred; however, cows administered bST had lower body condition scores at 42 wk postpartum. This trial demonstrated comparable effects of bST on lactational performance when administered daily or in a 14-d sustained-release vehicle.     

Performance and nutrient digestibility by dairy cows treated with bovine somatotropin and fed diets with steam-flaked sorghum or steam-rolled corn during early lactation

This study compared effects of exogenous bovine somatotropin (bST) on the performance of early lactation cows fed diets differing in ruminally degradable starch. Thirty-two Holstein cows (24 multiparous) in early lactation (5 d in milk) were divided into four groups and fed diets containing 39% grain as steam-flaked sorghum or steam-rolled corn with or without exogenous bST for 90 d. Grain processing did not affect dry matter intake as a percentage of body weight or yields of milk, but steam-rolled corn improved efficiency of feed utilization during the first 45 d of the study. Cows receiving bST had lower dry matter intake during the first 45 d of treatment. Milk yield and efficiency of feed utilization were increased by bST treatment, and milk yield response was greater during the first half than during the second half of the study. Milk composition and yield of milk components did not differ among treatments. Flaked sorghum increased in vitro starch hydrolysis and digestibilities of dry matter, organic matter, and starch, but neither method of grain processing nor bST affected digestibilities of crude protein, acid detergent fiber, or neutral detergent fiber. Grain type did not affect milk yield, and responses to bST were lower from 7 to 13 wk than from 1 to 6 wk prepartum.     

Lactation, health, and reproduction of dairy cows receiving daily injectable or sustained-release somatotropin.

Seventy-four Holstein cows (26 primiparous) were utilized to compare the efficacy and safety of sustained-release versus daily injectable formulations of recombinant bST. Twenty-four control cows were injected biweekly with oil microsphere; 25 cows were injected biweekly with 350 mg of bST microsphere; and 25 cows were injected daily with 10.3 mg of bST. Injections were initiated between wk 4 and 5 of lactation and continued for 280 d. Administration of bST caused a moderate increase in milk and FCM production and improved the efficiency of feed and energy conversions. Most health-related and reproduction-related variables did not differ among treatment groups. However, incidence of teat and udder disorders and feet and leg problems tended to be higher during the 40-wk injection period for the bST-treated cows than for the control cows. Incidence of GnRH therapy and number of days to first service were higher for daily bST-treated cows than for controls. No differences existed between sustained-release and daily bST-treated cows for any parameters monitored.     

Anti-idiotypic responses of lactating cows immunized with monoclonal antibodies against bovine somatotropin.

The objective of this study was to produce anti-idiotypic antibodies with bovine somatotropin (bST)-like activity by active immunization of lactating cows and to determine their effects on milk yield. Several monoclonal antibodies against bST were evaluated for their interaction with bST in a rat growth bioassay. Two bST-agonist monoclonal antibodies (1 and 2), and two bST-antagonist monoclonal antibodies (3 and 4) were selected. Cows were immunized with immunoglobulin G as a control (n = 12) or with one of the four anti-bST monoclonal antibodies (1, 2, 3, 4; n = 12) on d 3, 24, 45, 66, 87, 108, 129, and 150 of lactation. From wk 3 of lactation, all cows immunized with each of the four anti-bST monoclonal antibodies developed anti-idiotypes until wk 30 of lactation. Total lactation yields were not different among monoclonal antibodies 2, 3, and 4 and control cows (9299, 9321, 9733, and 9415 kg, respectively). However, cows immunized with anti-bST monoclonal antibody 1 had reduced lactation yield compared with cows on other treatments (8136 kg). Daily milk yield of cows immunized with monoclonal antibody 1 was decreased from wk 9 of lactation [36.2 vs. 40.9 kg/d (control)] until the end of lactation, concomitantly with decreased bST concentration from wk 9 of lactation. Cows immunized with anti-bST monoclonal antibody 4 had increased milk yield compared with that of controls during wk 3 to 6 and wk 18 to 21 of lactation. Therefore, anti-idiotypes directed against anti-bST 1 had bST-antagonistic effects on lactation performance; anti-idiotypes against anti-bST 4 transiently increased milk yield.     

Low doses of bovine somatotropin during the transition period and early lactation improves milk yield, efficiency of production, and other physiological responses of Holstein cows

The objectives of this experiment were to determine whether low doses of bovine somatotropin (bST) during the transition period and early lactation period improved dry matter intake (DMI), body weight (BW), or body condition score (BCS); provoked positive changes in concentrations of somatotropin, insulin, insulin-like growth factor-I (IGF-I), glucose, nonesterified fatty acids, and Ca; or improved milk yield (MY) response without obvious adverse effects on health status. Eighty-four multiparous Holstein cows completed treatments arranged in a 2 x 3 x 2 factorial design that included prepartum and postpartum bST, dry period (30 d dry, 30 d dry + estradiol cypionate, and 60 d dry), and prepartum anionic or cationic diets. Biweekly injections of bST began at 21 +/- 3 d before expected calving date through 42 +/- 2 d postpartum (control = 0 vs. bST = 10.2 mg of bST/d; POSILAC). At 56 +/- 2 d in milk, all cows were injected with a full dose of bST (500 mg of bST/14 d; POSILAC). During the prepartum period and during the first 28 d postpartum, no differences in mean BW, BCS, or DMI were detected between the bST treatment group and the control group. During the first 10 wk of lactation, cows in the bST treatment group had greater mean MY and 3.5% fat-corrected milk yield and lower SCC than did cows in the control group. When cows received a full dose of bST, an increase in milk production through wk 21 was maintained better by cows in the bST group. Mean concentrations of somatotropin, IGF-I, and insulin differed during the overall prepartum period (d -21 to -1). During the postpartum period (d 1 to 28), cows in the bST group had greater mean concentrations of somatotropin and IGF-I in plasma. Concentrations of Ca around calving did not differ because of bST treatment. Results suggest that changes in concentrations of blood measures provoked by injections of bST during the transition period and early lactation period resulted in improved metabolic status and production of the cows without apparent positive or negative effects on calving or health.     

Postparturient metabolic and production responses in cows previously exposed to long-term treatment with somatotropin.

Postparturient metabolic and production responses were studied for 85 multiparous cows consisting of controls and animals that had been previously exposed to long-term treatment with bST. Older cows previously exposed to bST at high doses (51.6 mg/d) had lower milk yields than controls. However, there were no significant differences compared with controls in milk yield for lower dose (17.2 mg/d) older cows or parity 2 cow groups. The bST-treated groups had higher postpartum DMI, lower serum FFA, lower serum beta-hydroxybutyrate levels, and higher serum glucose than controls. Some bST-exposed groups had lower milk fat but higher milk protein levels. All bST-treated groups had significantly lower ratios of C18 to C4 to 10 milk fatty acids. Control cows of both parity groups were in higher body condition and weighed more than bST-treated cows prior to calving. The differences in postpartum metabolism may be attributed to differences in body composition resulting from bST treatment in the prior lactation, because use of body condition score prior to calving as a covariate did not substantially alter responses. The control cows probably had greater reserves of mobilizable lipid. These contentions are supported by changes in milk composition for bST-treated cows, which were consistent with animals of greater appetite, mobilizing less lipid. The bST-treated cows were probably more energetically efficient milk producers because they produced milk from feed rather than from mobilization of tissue stores. These data suggest that bST use in a prior lactation may have potential benefit in reducing risk of metabolic disorders associated with lipid mobilization in the postparturient period.     

Comparison of somatotropin and growth hormone-releasing factor on milk yield, serum hormones, and energy status.

Holstein cows received 12 mg/d of growth hormone-releasing factor (continuous i.v. infusion, n = 5), 14 mg/d of bST (single daily i.m. injection, n = 8), or no treatment (controls, n = 8) for 60 d. Compared with controls (31.6 kg/d), bST and growth hormone-releasing factor increased milk yield to 34.2 and 37.0 kg/d, respectively. The increase in milk yield induced by the growth hormone-releasing factor was greater than that for bST. Milk yield was not different among groups following cessation of treatment. Milk energy output was 24.2 Mcal/d in controls, and growth hormone-releasing factor increased milk energy output to 28.5 Mcal/d. Milk energy output of cows receiving bST was 26.1 Mcal/d. Growth hormone-releasing factor increased DMI (23.2 kg/d) over that of controls (21.1 kg/d), whereas bST (21.5 kg/d) did not. Relative to controls, bST increased averaged daily serum somatotropin from 1.3 to 7.6 ng/ml and insulin-like growth factor-I from 67.5 to 116.0 ng/ml. Relative to bST, growth hormone-releasing factor increased serum somatotropin to 16.3 ng/ml and insulin-like growth factor-I to 202.6 ng/ml. Relative to control (115.8 meq/dl) and bST (158.1 meq/dl), growth hormone-releasing factor increased plasma NEFA (230.3 meq/dl). During treatment, calculated energy balance was negative for cows receiving growth hormone-releasing factor but positive for bST and control cows. Milk composition, body condition score, BW, and apparent digestibility of DM were not different among treatments. We conclude that i.v. infusion of 12 mg/d mg of growth hormone-releasing factor has greater galactopoietic activity than i.m. injections of 14 mg/d of bST.(ABSTRACT TRUNCATED AT 250 WORDS)     

Use of recombinant bovine somatotropin for up to two consecutive lactations on dairy production traits

Fifteen (control) cows were injected with saline; 28 cows were treated with rbST (15 with 10.3 and 13 with 20.6 mg/d). Fourteen of the 28 treated cows had between injected with rbST in the previous lactation. A total of 29 cows in the present trial had not received rbST in previous lactation. Treatment injections were started between wk 4 and 5 of lactation and continued for 266 consecutive days. Milk production, fee intake and efficiency, and BW data were recorded for 3 wk before and 3 wk after a 38-wk rbST treatment period. Administration of rbST increased average FCM yields in the current lactation by 19%, increased feed energy intake by 7%, and decreased feed conversion (energy intake per unit FCM output) by 17%. Previous treatment with rbST did not significantly affect current milk production but caused a nonsignificant increase in feed intake and a significant, unfavorable, increase in feed conversion of 12%. The results suggest that the advantages of rbST in terms of increased milk yield are maintained for a second consecutive lactation of rbST administration. However, the advantages of rbST in terms of improved feed conversion may be substantially reduced in a second consecutive lactation of administration.     

Response of dairy cows to high doses of a sustained-release bovine somatotropin administered during two lactations. 1. Production response.

This study evaluated the effect of sometribove (zinc methionyl bST) in a sustained-release formulation administered to lactating cows at concentrations up to 3.0 g every 14 d over two lactations. Eighty-two lactating Holstein cows in their first, second, or third lactation were assigned to the study. Cows received .6, 1.8, or 3.0 g of bST in one, three, or five intramuscular injections of a unit dose (.6 g) every 2 wk. Controls received five injections of the vehicle (equivalent volume to the 3.0-g treatment) every 2 wk. Injections were administered from 60 +/- 3 d postpartum until dry-off or necropsy. Thirty-eight animals were continued on treatment for a second consecutive lactation. During the 1st yr of treatment, bST increased mean 3.5% FCM by 7.2, 9.4, and 8.4 kg/d over control production (21.1 kg/d). During the 2nd yr, milk response to .6, 1.8, and 3.0 g of bST averaged 10.6, 3.6, and 4.9 kg/d over controls (24.8 kg/d). The incidence of clinical mastitis increased in the 3.0-g group relative to controls during the 2nd yr. Thus, salable FCM averaged 8.1, 9.1, and 6.2 kg/d above controls (yr 1) and 12.1, 4.7, and -2.8 kg/d (yr 2) for the .6-, 1.8-, and 3.0-g groups. Salable FCM was unaffected by mastitis at a proposed commercial dose (.6 g). Milk fat, protein, lactose, calcium, phosphorus, zinc, magnesium, and ash concentrations were unaffected by bST treatment. Calculated energy, calcium, phosphorus, and protein balances also were unaffected except for early decreases of up to 5 Mcal/d, and 40, 20, and 600 g/d, respectively, until feed intake increased. Milk serum bST concentrations greater than the assay limit of sensitivity (1 ng/ml) were routinely measurable only at doses of 1.8 and 3.0 g. Results confirmed that bST concentrations in milk serum are exceedingly small. Overall, supraphysiological doses of sometribove increased milk production with little effect on composition. No toxic effects of bST were observed.